Wealth Enhancement Advisory Services LLC Has $3.51 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Wealth Enhancement Advisory Services LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 11.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,322 shares of the medical device company’s stock after purchasing an additional 2,591 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in DexCom were worth $3,512,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of DXCM. Stableford Capital II LLC lifted its position in DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after acquiring an additional 88 shares during the last quarter. D Orazio & Associates Inc. lifted its position in shares of DexCom by 0.8% during the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after purchasing an additional 93 shares during the last quarter. Gulf International Bank UK Ltd boosted its stake in DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after purchasing an additional 93 shares during the period. EverSource Wealth Advisors LLC grew its holdings in DexCom by 10.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after buying an additional 98 shares during the last quarter. Finally, Harbor Investment Advisory LLC increased its position in DexCom by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after buying an additional 100 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $112.49 on Wednesday. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The firm has a market cap of $44.74 billion, a PE ratio of 72.57, a price-to-earnings-growth ratio of 2.77 and a beta of 1.16. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company’s 50-day moving average price is $122.32 and its two-hundred day moving average price is $125.58.

DexCom (NASDAQ:DXCMGet Free Report) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. On average, equities analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Raymond James raised their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Redburn Atlantic began coverage on shares of DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price for the company. UBS Group lifted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $140.33.

Check Out Our Latest Report on DexCom

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the sale, the chief executive officer now owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 49,633 shares of DexCom stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the sale, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,735 shares of company stock worth $7,619,347. 0.30% of the stock is owned by corporate insiders.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.